Our laboratory is devoted to investigating the pathogenesis and immune response to mycobacterial species, especially M. tuberculosis, with the main interest in the immune responses induced by vaccines. More recently, our knowledge and expertise evaluating the cellular and molecular immune responses to Bacille Calmette-Guerin (BCG) and additional anti-TB vaccine candidates, is being applied to evaluate novel vaccine candidates and therapeutics against SARS-CoV-2 (causative agent of COVID-19).
In our laboratory, we have the ability to test how effective the immune response is against different clinical strains of bacterial and viral infections. Our goal is to better understand the immune response to different vaccine candidates using multiparametric and transcriptional unbiased analysis of the cells induced after vaccination. We also utilize metabolic profiles, high throughput and histologic methods, and computational tools to evaluate immune responses.
Furthermore, as the director of the CSU Flow Cytometry and Cell Sorting facility and due to our lab experience using flow cytometry as an analytical tool, our laboratory has been implementing and developing new tools for multicolor flow cytometry analysis. We are currently using algorithms that automatically identify cell populations according to their marker expression profiles. These computational methods not only can identify rare populations, but also to match cell populations across samples, and statistically compare features between different populations. The algorithms we recently published in Scientific Reports (Cyto-Feature Engineering: A Pipeline for Flow Cytometry Analysis to Uncover Immune Populations and Associations with Disease) provides an unsupervised analysis, allowing an unbiased investigation of cytometry data.
Immune Mechanisms of Protection Against Mycobacterium tuberculosis Center (IMPAC-TB)
The Henao Tamayo and Podell labs are leading a CSU team on a $1.2 million subcontract to accelerate research progress in tuberculosis vaccines. Objectives are to understand the immune responses that prevents initial infection, the establishment of latent infection, and the transition to active TB disease. There is currently only one vaccine for TB and it only reliably works on children.
Vaccine induced memory immunity in tuberculosis
There are several vaccine candidates that give protection against the laboratory strains H37Rv and Erdman at a level comparable to the BCG vaccine. However, whether different vaccine types give equivalent or different levels of memory T cell subsets is unknown, and whether these vaccines will be equally protective against newly emerging highly virulent clinical strains is equally unaddressed.view project
Comprehensive Immune Profiling Reveals CD56+ Monocytes and CD31+ Endothelial Cells Are Increased in Severe COVID-19 Disease.
Dutt TS, LaVergne SM, Webb TL, Baxter BA, Stromberg S, McFann K, Berry K, Tipton M, Alnachoukati O, Zier L, Ebel G, Dunn J, Henao-Tamayo M, Ryan EP.
J Immunol. 2022 Feb 1;208(3):685-696. doi: 10.4049/jimmunol.2100830. Epub 2022 Jan 5. PMID: 34987111
Rijkers GT, Weterings N, Obregon-Henao A, Lepolder M, Dutt TS, van Overveld FJ, Henao-Tamayo M.
Vaccines (Basel). 2021 Aug 3;9(8):848. doi: 10.3390/vaccines9080848. PMID: 34451973
A longitudinal SARS-CoV-2 biorepository for COVID-19 survivors with and without post-acute sequelae.
LaVergne SM, Stromberg S, Baxter BA, Webb TL, Dutt TS, Berry K, Tipton M, Haberman J, Massey BR, McFann K, Alnachoukati O, Zier L, Heacock T, Ebel GD, Henao-Tamayo M, Dunn J, Ryan EP.
BMC Infect Dis. 2021 Jul 13;21(1):677. doi: 10.1186/s12879-021-06359-2. PMID: 34256735
A Whole Virion Vaccine for COVID-19 Produced via a Novel Inactivation Method and Preliminary Demonstration of Efficacy in an Animal Challenge Model.
Ragan IK, Hartson LM, Dutt TS, Obregon-Henao A, Maison RM, Gordy P, Fox A, Karger BR, Cross ST, Kapuscinski ML, Cooper SK, Podell BK, Stenglein MD, Bowen RA, Henao-Tamayo M, Goodrich RP.
Vaccines (Basel). 2021 Apr 1;9(4):340. doi: 10.3390/vaccines9040340. PMID: 33916180
Subunit vaccine protects against a clinical isolate of Mycobacterium avium in wild type and immunocompromised mouse models.
Larsen SE, Reese VA, Pecor T, Berube BJ, Cooper SK, Brewer G, Ordway D, Henao-Tamayo M, Podell BK, Baldwin SL, Coler RN.
Sci Rep. 2021 Apr 27;11(1):9040. doi: 10.1038/s41598-021-88291-8. PMID: 33907221
Lab Principal Investigator (PI)
Director, Diversity, Equity and Inclusion, CU Medical School - Fort Collins Branch
Director, CSU Flow Cytometry Facility
Co-Director, Mycobacteria Research Laboratories
Research Scientist I
Research Associate III
CSU Flow Cytometry Core Manager
Research Associate I
Research Associate I
Research Associate I
Graduate Research Assistant
news and updates
Marcela Henao-Tamayo was recognized as an outstanding faculty member at Colorado State University and named a 2022-2024 Monfort Professor.
Marcela Henao-Tamayo discusses her tuberculosis research, COVID-19 vaccine projects and Women’s History Month with Colorado State University.
While Marcela Henao Tamayo’s ongoing primary research focus is on tuberculosis, she is currently working with colleagues on developing a COVID-19 vaccine. Her conversation with CSU President Joyce McConnell highlights the scope, caliber and impact of CSU research.
Lab: Microbiology room C210
Office: Microbiology room C221